Trefoil Therapeutics
Trefoil, a biotech firm, pioneers regenerative treatments for corneal diseases using eFGF-1 technology.
Founded
2014Trefoil, a biotech firm, pioneers regenerative treatments for corneal diseases using eFGF-1 technology.
Trefoil Therapeutics is a biotechnology company dedicated to developing regenerative pharmacologic treatments for corneal diseases using its engineered fibroblast growth factor-1 protein (eFGF-1) technology platform. The company aims to restore sight to millions affected by corneal diseases by leveraging the regenerative properties of corneal endothelial and epithelial cells. Trefoil's market focus includes advancing two products based on TTHX1114 to address various corneal conditions affecting both the front and back surfaces of the cornea.
Trefoil Therapeutics has made significant strides in the field of ophthalmology, positioning itself as a leader in regenerative treatments for corneal diseases. The company's innovative approach has the potential to reduce preventable blindness and improve the quality of life for many individuals. Trefoil's advancements in eFGF-1 technology have garnered attention within the biotech community, contributing to its growing reputation as a pioneer in regenerative medicine.
Companies similar to Trefoil Therapeutics include Claris Biotherapeutics, RegeneRx Biopharmaceuticals, EyeCyte and TRex Bio.
Trefoil Therapeutics was founded in 2014.
Trefoil Therapeutics' headquarters is located in San Diego, CA, US.
Trefoil Therapeutics' most recent funding round was for $12M (USD) in March 2022.
As of Mar 22, 2022, Trefoil Therapeutics has disclosed funding of $85.8M (USD). Undisclosed round amounts are excluded.
Trefoil Therapeutics has 18 employees as of Feb 5, 2024.
TRex Bio
trex.bio
